Kura Spins Out Caspian Therapeutics with $50M Series A, Retains 49.2% Stake
KURA sits 72% above its 52-week low of $7.358.
Summary
Kura Oncology spun out its menin inhibitor diabetes program into Caspian Therapeutics, which raised $50 million in Series A funding. Kura invested $4.3 million and retains a 49.2% stake.
Key Events · M&A and Partnerships · KURA
-
Caspian Therapeutics $50M Series A Closed
Caspian completed a $50.0 million Series A preferred stock financing on September 8, 2026. Kura invested $4.3 million and holds approximately 49.2% of Caspian's outstanding capital stock post-financing.
-
Contribution and License Agreement Executed
Kura contributed next-generation menin inhibitor assets, including KO-7246, to Caspian in exchange for common stock and up to $1.5 million in cost reimbursement. Cross-licenses grant each party royalty-free rights in their respective fields.
-
Intercompany Services Agreement
Kura will provide R&D, administrative, and other services to Caspian for fees. Initial term is one year with automatic annual renewals unless either party gives 90 days' notice.
-
Strategic Rationale
The structure shifts development, regulatory, and commercialization costs for the diabetes/cardiometabolic menin inhibitor program to Caspian while Kura retains a significant equity stake and service-fee revenue.
Analysis · KURA · Life Sciences
Kura Oncology has formally separated its next-generation menin inhibitor program for diabetes and cardiometabolic diseases into Caspian Therapeutics, a separately financed subsidiary. Caspian closed a $50 million Series A on September 8, 2026, with Kura investing $4.3 million and retaining approximately 49.2% ownership. The structure offloads development costs for a non-core program while preserving significant upside exposure. The contribution agreement transfers KO-7246 and related IP to Caspian in exchange for common stock and up to $1.5 million in cost reimbursement, and a services agreement keeps Kura as a paid R&D and administrative provider for at least one year. This follows the September 9 news release announcing the launch and adds the concrete financing and ownership terms investors need to assess the transaction.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KURA was trading at $12.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.36 to $13.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.